Molecular Systems Biology (Feb 2022)

CFTR interactome mapping using the mammalian membrane two‐hybrid high‐throughput screening system

  • Sang Hyun Lim,
  • Jamie Snider,
  • Liron Birimberg‐Schwartz,
  • Wan Ip,
  • Joana C Serralha,
  • Hugo M Botelho,
  • Miquéias Lopes‐Pacheco,
  • Madalena C Pinto,
  • Mohamed Taha Moutaoufik,
  • Mara Zilocchi,
  • Onofrio Laselva,
  • Mohsen Esmaeili,
  • Max Kotlyar,
  • Anna Lyakisheva,
  • Priscilla Tang,
  • Lucía López Vázquez,
  • Indira Akula,
  • Farzaneh Aboualizadeh,
  • Victoria Wong,
  • Ingrid Grozavu,
  • Teuta Opacak‐Bernardi,
  • Zhong Yao,
  • Meg Mendoza,
  • Mohan Babu,
  • Igor Jurisica,
  • Tanja Gonska,
  • Christine E Bear,
  • Margarida D Amaral,
  • Igor Stagljar

DOI
https://doi.org/10.15252/msb.202110629
Journal volume & issue
Vol. 18, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a chloride and bicarbonate channel in secretory epithelia with a critical role in maintaining fluid homeostasis. Mutations in CFTR are associated with Cystic Fibrosis (CF), the most common lethal autosomal recessive disorder in Caucasians. While remarkable treatment advances have been made recently in the form of modulator drugs directly rescuing CFTR dysfunction, there is still considerable scope for improvement of therapeutic effectiveness. Here, we report the application of a high‐throughput screening variant of the Mammalian Membrane Two‐Hybrid (MaMTH‐HTS) to map the protein–protein interactions of wild‐type (wt) and mutant CFTR (F508del), in an effort to better understand CF cellular effects and identify new drug targets for patient‐specific treatments. Combined with functional validation in multiple disease models, we have uncovered candidate proteins with potential roles in CFTR function/CF pathophysiology, including Fibrinogen Like 2 (FGL2), which we demonstrate in patient‐derived intestinal organoids has a significant effect on CFTR functional expression.

Keywords